首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   262960篇
  免费   41591篇
  国内免费   8480篇
耳鼻咽喉   6187篇
儿科学   7121篇
妇产科学   3461篇
基础医学   15254篇
口腔科学   3457篇
临床医学   40533篇
内科学   62389篇
皮肤病学   9158篇
神经病学   19749篇
特种医学   11104篇
外国民族医学   26篇
外科学   51030篇
综合类   21632篇
现状与发展   94篇
一般理论   7篇
预防医学   17076篇
眼科学   5974篇
药学   13358篇
  82篇
中国医学   6400篇
肿瘤学   18939篇
  2024年   887篇
  2023年   5719篇
  2022年   3857篇
  2021年   6786篇
  2020年   8818篇
  2019年   4642篇
  2018年   10001篇
  2017年   10051篇
  2016年   11305篇
  2015年   12959篇
  2014年   21418篇
  2013年   22054篇
  2012年   15063篇
  2011年   15591篇
  2010年   18102篇
  2009年   20908篇
  2008年   13632篇
  2007年   11821篇
  2006年   13629篇
  2005年   10108篇
  2004年   8023篇
  2003年   7099篇
  2002年   6136篇
  2001年   6929篇
  2000年   5446篇
  1999年   4818篇
  1998年   4536篇
  1997年   4407篇
  1996年   3999篇
  1995年   3749篇
  1994年   2404篇
  1993年   1871篇
  1992年   1719篇
  1991年   1699篇
  1990年   1313篇
  1989年   1395篇
  1988年   1194篇
  1987年   1016篇
  1986年   1007篇
  1985年   848篇
  1984年   614篇
  1983年   580篇
  1982年   553篇
  1981年   435篇
  1980年   381篇
  1979年   347篇
  1978年   364篇
  1977年   410篇
  1975年   294篇
  1972年   310篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
目的:探讨凝血因子ⅩⅢ(FⅩⅢ)Val34Leu基因多态性与中国人群深静脉血栓形成(DVT)发病的相关性.方法:利用聚合酶链反应和限制性片段长度多态性(PCR-RFLP)方法,检测了103例DVT患者与106例正常对照的FⅩⅢVal34Leu基因多态,并加以对照分析.结果:103例DVT患者FⅩⅢVa134Leu基因型均为野生型V/V,未见突变类型;106例对照组中发现1例突变杂合子V/L.2组基因型频率、等位基因频率相互比较,差异均无统计学意义(P>0.05).结论:FⅩⅢVal34Leu对中国人群DVT有保护作用的可能性极小.  相似文献   
992.
993.
Tissue-engineered skin substitutes such as Apligraf have emerged over the past 20 years as among the most carefully studied and efficacious of the advanced wound modalities. These products have been proven as effective enhancements to general wound care, promoting wound closure particularly in instances where conventional wound care fails. Marketed for hard-to-heal wounds since 1998, Apligraf has become part of standard wound care in many wound centers across the United States. Despite this situation, few general wound care guidelines incorporate advanced and active wound-healing technologies, such as tissue-engineered skin products. Because of this deficiency, appropriate patient selection and proper use of these product remain largely unaddressed within the general wound care community. Here, we describe the development of guidelines surrounding optimal use of the bilayered living cell therapy, Apligraf, in the treatment of the two types of lower extremity ulcers for which the product is FDA approved: venous leg ulcer and diabetic foot ulcer. The guidelines detailed in this article focus on the identification and selection of patients who are at risk for failure of standard wound care therapy and thus appropriate for Apligraf treatment. The intended audience for these guidelines is the general wound care practitioner, for whom the developed treatment algorithms and accompanying figure legends should provide practical, user-friendly direction simplifying both patient selection and appropriate use of Apligraf within the context of good wound-healing practice.  相似文献   
994.
995.
背景:儿童和青少年超重和肥胖正迅速增加。在该人群,单纯行为疗法减肥及维持体重下降的效果有限,但是对药物治疗尚未进行广泛的研究。 目的:确定奥利州他(Orlistat)在青少年体重治疗方面的效果及其安个性。 设计、地点和病例:于美国和加拿大32个中心、539例肥胖青少年(12—16岁;体重指数[body mass index,BMI]在第95百分化之上≥2单位)进行的多ln0、54剧(2000年8月至2002年10月)随机双盲研究。 干预:给予奥利司他(n=357)或安慰剂(n=182)120mg,每口3次,持续1年;加适度低热卡饮食(脂肪占30%)、运动和行为治疗。 主要观察指标:BMI变化;二级指标包括腰围和髋用、体重下降、脂质测量以及机体对口服葡萄糖的血糖和胰岛素反心。 结果:至12周时,两组BMI均有下降;此后,奥利司他组体重维持稳定而安慰剂组则超过基线。研究结束时,奥利司他组BMI下降0.55。而安慰剂组则增加0.31(P=0.001)。与安慰剂组的15.7%相比,奥利司他组26.5%的病例BMI下降≥5%(P=0.005);BMI下降≥10%者分别为4.5%和13.3%(P=0.002)。在研究结束时,奥利司他组体重增加0.53kg,安慰剂组增加3.14kg(P〈0.001)。双能X线吸收测量娃示,这种差异可用脂肪体再的变化解释。奥利司他组腰围下降,安慰剂组腰围上升(-1.33cm比+0.12cm;P〈0.05)。奥利司他组发生轻至中度胃肠道不良事件者为9%-50%,安慰剂组为1%~13%。 结论:与安慰剂比较,奥利司他与饮食、运动和行为改善联合可显著改善肥胖青少年体重的治疗。在这个青少年人群,连续使用奥利司他1年并无重要安全问题,尽管奥利司他组胃肠道不良事件较为常见。  相似文献   
996.
Intracranial Angioplasty and Stenting in the Awake Patient   总被引:1,自引:0,他引:1  
BACKGROUND AND PURPOSE: Endovascular treatment for intracranial atherosclerosis is evolving, but complications remain an issue. Most interventions are performed under general anesthesia, preventing intraprocedural clinical evaluations. We describe our approach to intracranial angioplasty and stenting, using local rather than general anesthesia, and intraprocedural neurological assessment. METHODS: We prospectively collected procedural and outcome information on all patients undergoing intracranial angioplasty and stenting. Patients underwent interventions under local anesthesia with mild intravenous sedation or analgesia only if needed. Intraoperative neurological evaluations were performed, and symptomatology was used to guide the interventional technique. RESULTS: Forty-eight arteries in 40 patients with a mean age of 65.2 years were treated. Thirty-two anterior and 16 posterior circulation segments were treated. Technical success was achieved in 100% of patients with reduction of the mean pretreatment stenosis from 85 +/- 8.6% to 7 +/- 10.1%. Stents were deployed in 40 segments; five patients were treated with drug-eluting stents. The cobalt-chromium coronary stents were the easiest to deliver. Thirty-seven patients were treated under local anesthesia and, of those, 61.4% experienced intraprocedural symptoms that led to some alteration of the interventional technique. Headache was the most common symptom, and, when persistent, it heralded the occurrence of subarachnoid hemorrhage. There were seven total neurological complications, but only five (10.5%) led to permanent morbidity (4 strokes) or mortality (1 death). CONCLUSIONS: Intracranial angioplasty and stenting can be successfully performed using coronary techniques and equipment including drug-eluting stents. Local anesthesia permits neurological evaluations and often leads to the adjustment of the interventional technique, potentially making the procedure safer.  相似文献   
997.
998.
OBJECTIVE: Redistribution hypothermia adversely affects hemodynamics and postoperative recovery in patients undergoing cardiac surgery. In off-pump coronary bypass surgery (OPCAB), maintaining the temperature is important because warming by cardiopulmonary bypass is omitted. Pre-warming studies reported earlier showing pre-warming as an effective means of preventing redistribution hypothermia was time consuming since it required at least 1-2h to pre-warm the patients before the surgery. Because pre-warming for such a long time is impractical in clinical practice, this study evaluated the efficacy of active warming during the preanesthetic period for the prevention of redistribution hypothermia in the early operative period of OPCAB. METHODS: After gaining the approval of Institutional Review Board and informed consent from the patients, 40 patients undergoing OPCAB were divided into control and pre-warming groups. The patients in control group (n=20) were managed with warm mattresses and cotton blankets, whereas patients in pre-warming group (n=20) were actively warmed with a forced-air warming device before the induction of anesthesia. Hemodynamic variables and temperature were recorded before anesthesia (Tpre) and at 30 min intervals after anesthesia for 90 min (T30, T60, and T90). RESULTS: Active warming duration was 49.7+/-9.9 min. There were no statistically significant differences in skin temperature, core temperature and hemodynamic variables between the two groups at preinduction period except for mean arterial pressure and central venous pressure. The core temperature at T30, T60, and T90 was statistically higher in pre-warming group than that in control group. Core temperature of six (30%) and seven patients (35%) in control group was reduced below 35 degrees C at T60 and T90, respectively, whereas core temperature of only one patient (5%) in pre-warming group was reduced below 35 degrees C at T90 (P=0.02). CONCLUSIONS: Active warming using forced air blanket before the induction of anesthesia reduced the incidence and degree of redistribution hypothermia in patients undergoing OPCAB. It is a simple method with reasonable cost, which does not delay the induction of anesthesia nor the surgery.  相似文献   
999.
1000.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号